Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
Wegovy may cause rare mood changes such as depression or anxiety. For Black women, stigma, underdiagnosis, and healthcare inequities can make these symptoms harder to recognize and address. Key strategies to protect emotional well-being include:
Recognizing warning signs early and practicing consistent self-care can help you stay emotionally resilient while on Wegovy.
Because mood symptoms can be subtle—and easily dismissed or misdiagnosed—getting a clear, personalized read on what you're experiencing is a critical first step. A free, instant, online symptom check takes just a few minutes, uses your specific symptoms to identify possible causes, and helps you decide what to do next. It's a smart, private way to advocate for yourself before your next doctor's visit.
Reviewed for medical accuracy: 07/21/2026
Wegovy (semaglutide) is a prescription medication approved for chronic weight management. Many people experience significant benefits, but some users report changes in mood, including feelings of depression or anxiety. As a Black woman, you may face unique challenges in recognizing and addressing mental health symptoms. This guide will help you understand potential mood changes, spot warning signs, and take action early.
Wegovy works by mimicking the hormone GLP-1, which helps control appetite and blood sugar. While most side effects relate to digestion (nausea, diarrhea, constipation), there are rare reports of mood shifts:
It's important to remember that not everyone on Wegovy will experience mood changes. However, being proactive can help you stay emotionally resilient.
Tracking your mental health is as important as monitoring your physical symptoms. Watch for these red flags:
If you notice several of these symptoms persisting for more than two weeks, they may signal a mood disorder.
Black women encounter unique stressors and barriers in mental health care:
Because of these factors, you might be less likely to seek help until symptoms are severe. Early recognition and intervention can prevent escalation.
Keep a Mood Journal
Use a Tracking App or Symptom Checker
Schedule Regular Check-Ins with Your Doctor
Build a Support Network
Practice Stress-Reduction Techniques
Not every mood shift requires a psychiatrist, but you should act promptly if you notice:
If you experience any of the above, contact your doctor or mental health professional right away. In an emergency, call 911 or go to the nearest emergency department.
Honest communication with your healthcare providers is vital:
If you feel your concerns are not taken seriously, consider seeking a second opinion or finding a provider who specializes in women's mental health or serves diverse communities.
Wegovy offers significant benefits for many people:
However, any medication can carry risks. Recognizing and addressing mood changes early helps ensure you reap the benefits of Wegovy without compromising your emotional well-being.
• Stick to a balanced, nutrient-rich diet that supports stable blood sugar.
• Aim for 7–9 hours of quality sleep each night; establish a calming bedtime routine.
• Engage in regular physical activity that you enjoy—dance, swimming, walking.
• Allocate time for hobbies and social connections.
• Consider teletherapy if in-person care is difficult to access.
Always remember: if you're uncertain about any symptom—physical or mental—talk to a doctor. Your well-being matters, and early action can make all the difference.
(References)
* Sun, H., Su, S., Zhou, J., Li, Y., Zhao, Y., & Li, R. (2023). Psychiatric adverse events of GLP-1 receptor agonists: A systematic review and meta-analysis. *Frontiers in Pharmacology*, *14*, 1243759. PMID: 38046897.
* Xu, Y., Zhang, W., Zhang, X., Li, B., & Zhang, Y. (2023). Adverse Events Associated with Semaglutide: A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Data. *Journal of Clinical Pharmacology*, *63*(10), 1133–1145. PMID: 37341857.
* Hassan, M., Aboraya, A., Almuwaqqat, Z., Ghandour, R., Boustani, M., Almuwaqqat, Z., ... & Elsayed, H. (2022). Racial and ethnic disparities in mental health care among adults with obesity: An analysis of the Medical Expenditure Panel Survey. *Obesity Research & Clinical Practice*, *16*(4), 312-319. PMID: 35840398.
* Lee, P. K., Chang, C. Y., Rhee, B. H., & Kim, H. G. (2023). Racial and ethnic differences in adverse event reporting for obesity medications in the FDA Adverse Event Reporting System. *International Journal of Clinical Pharmacy*, *45*(4), 987–997. PMID: 37194886.
* Jalily, M., Rahmani, K., Pormehr-Barzoki, T., Azarfar, A., & Khosravi, A. R. (2023). Mental Health Outcomes of GLP-1 Receptor Agonists: A Systematic Review. *Psychopharmacology Bulletin*, *53*(3), 101–110. PMID: 38240030.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.